NPSP


Wedbush Reiterates Neutral On NPS Pharmaceuticals Despite FDA Approval For Natpara

Wedbush analyst David Nierengarten was out with some neutral comments on NPS Pharmaceuticals (NASDAQ:NPSP), following the news that the company’s Natpara has been approved by the FDA to …

NPSP: FDA Approves Natpara® for Injection in Patients with Hypoparathyroidism

(BUSINESS WIRE)– NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, …

Oppenheimer Comments On NPS Pharma In Light Of Shire Takeover

Oppenheimer healthcare analyst Rohit Vanjani weighed in today with his thoughts on NPS Pharma (NASDAQ:NPSP), after the company and Shire (NASDAQ:SHPG) announced a definitive merger agreement whereby …

Oppenheimer Reiterates Outperform On NPS Pharmaceuticals Following 3Q14 Results

Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of $40, which represents a potential upside …

Brean Capital Reiterates Buy On NPS Pharmaceuticals Following 3Q14 Results

In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …

Wedbush Sets Expectations On NPS Pharmaceuticals Heading Into Q314 Earnings Release

In a research report issued Thursday, Wedbush analyst David Nierengarten maintained an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of …

NPS Pharma: Rems Concern? Overblown, Says Canaccord

In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of NPS Pharma (NASDAQ:NPSP) with a $42 price target, following concerns …

Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval

In a report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $37 fair value, following last friday’s news …

Brean Capital Reiterates Buy On NPS Pharmaceuticals On The Back Of FDA Panel Outcome

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …

Janney Capital Reiterates Buy On NPS Pharma Ahead Of FDA Meeting For Natpara

In a research note published yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharma (NASDAQ:NPSP) with a $37 fair …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts